KNSA Q1 2024 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena

KNSAKiniksa Pharmaceuticals, Ltd.

$3B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$80M+65.2% YoY

Gross Profit

$48M60.5% margin

Operating Income

-$17M-20.7% margin

Net Income

-$18M-22.2% margin

EPS (Diluted)

$-0.25

QoQ Revenue Growth

-4.2%

Cash Flow

Operating Cash Flow

$4M

Free Cash Flow

$4M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$520M

Total Liabilities

$88M

Stockholders' Equity

$432M

Cash & Equivalents

$141M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$80M	$48M	+65.2%
Gross Profit	$48M	$32M	+51.5%
Operating Income	-$17M	-$11M	-47.7%
Net Income	-$18M	-$12M	-44.3%

Revenue Segments

Product

$79M99%

Collaboration

$973,0001%